AOD-9604 vs Pramlintide

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and investigated as a candidate anti-obesity compound on the premise that the lipolytic activity of hGH resides in this C-terminal domain — separable from the growth-promoting and insulin-antagonizing effects mediated by other regions of the full-length molecule. AOD-9604 is proposed to stimulate fat metabolism through beta-3 adrenergic receptor-mediated pathways without activating IGF-1 production or the anabolic receptor domains of full-length GH, making it theoretically safer than GH itself for metabolic applications; preclinical studies in obese mice demonstrated lipolytic effects and body weight reduction. Clinical trials were conducted in humans by Metabolic Pharmaceuticals, and Phase 2/3 data generated in Australia suggested modest weight loss effects; however, the primary trial results were never published in PubMed-indexed peer-reviewed journals, and the best indexed primary evidence for AOD-9604 remains a preclinical study in obese mice demonstrating effects on lipid metabolism. AOD-9604 has no FDA approval and no approved indication in any jurisdiction; despite its human clinical program, the absence of published peer-reviewed primary trial data means clinical efficacy and safety cannot be independently evaluated, and the compound is currently available only as a research peptide. AOD-9604 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water before subcutaneous administration; the volume of BAC water added to the vial determines the concentration of the resulting solution, following standard peptide reconstitution methodology. Research on AOD-9604 peptide dosage was conducted in both the preclinical obese-mouse model and the Phase 2/3 human clinical program in adult obesity populations; clinical trial dosage data exists from the Metabolic Pharmaceuticals program, though primary results were not published in indexed peer-reviewed journals. Oral formulations of AOD-9604 were also evaluated in the clinical program as an alternative to subcutaneous delivery. AOD-9604 dosage context In the Metabolic Pharmaceuticals clinical program, AOD-9604 was evaluated at oral doses of 1mg and 9mg daily, and via subcutaneous injection at approximately 1mg/day in Phase 2/3 human obesity studies. In the research peptide community, subcutaneous protocols commonly reference 250–300mcg once daily, administered to the subcutaneous adipose tissue of the abdomen. These figures derive from the research context rather than an approved clinical protocol — AOD-9604 has no approved dosing for any human indication. Reconstitution follows standard peptide preparation: a 5mg vial combined with 2mL bacteriostatic water yields 2,500mcg/mL (0.1mL = 250mcg per injection). Oral formulations were evaluated in the clinical trial as a potential non-injectable route; no commercial oral AOD-9604 product exists. AOD-9604 side effects and safety profile The safety data from AOD-9604's clinical program includes several notable findings: no elevation in IGF-1 levels was observed at studied doses — a key distinction from full-length growth hormone, where IGF-1 elevation drives concerns about cell proliferation and potential oncogenicity. No significant disruption of fasting glucose or insulin sensitivity was documented. No serious adverse events attributable to AOD-9604 were reported in published trial summaries. The absence of anabolic receptor activity (no binding to the GH receptor growth-promoting domain) is the proposed basis for this benign safety profile compared to GH itself. Long-term safety data does not exist due to the absence of Phase 3 completion and product approval. Research-grade AOD-9604 carries standard purity and contamination risks associated with unregulated compounding. Providers offering AOD-9604 through supervised clinical programs are searchable in the PeptideBase provider directory.

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved by the FDA as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes, and investigated for weight management due to amylin's central role in meal-related satiety signaling. Amylin is co-secreted with insulin from pancreatic beta-cells and slows gastric emptying, suppresses post-meal glucagon release, and activates satiety circuits in the area postrema and nucleus tractus solitarius of the brainstem. Randomized controlled trials demonstrate that subcutaneous pramlintide administration before meals significantly reduces 24-hour caloric intake, meal sizes, and body weight in obese subjects, with effects independent of glycemic control. Pramlintide is an FDA-approved prescription medication (Symlin); its weight management application is off-label in non-diabetic patients, and use requires monitoring for hypoglycemia, particularly when co-administered with insulin. Pramlintide vs cagrilintide: the amylin analogue generation gap Pramlintide (Symlin) is a first-generation amylin analogue with a short half-life requiring injection before each meal — typically 60–120mcg per meal in T1D, or 120mcg per meal in T2D — making three daily injections standard. Cagrilintide, currently in Phase 3 development, is a long-acting amylin analogue designed for once-weekly subcutaneous administration, combining with semaglutide in the CagriSema combination. The practical distinction is significant: pramlintide's thrice-daily injection burden limits adherence, particularly in non-diabetic weight management contexts. Cagrilintide's weekly dosing removes this barrier and enables combination with a weekly GLP-1 agonist in a single injection protocol. Pramlintide for weight management: In adults without diabetes, pramlintide produces modest mean weight reductions of 3–5% over 6-month studies — less than GLP-1 agonists but with a complementary mechanism. Some researchers have combined pramlintide with a GLP-1 agonist (pramlintide + GLP-1) as an early-generation dual amylin/incretin approach, reporting additive weight reductions. CagriSema (cagrilintide + semaglutide) in Phase 3 represents the pharmacologically optimised version of this dual approach, with superior efficacy and weekly dosing. Pramlintide's practical role in new weight management programs has therefore narrowed significantly as cagrilintide and GLP-1/amylin combinations approach approval.